141 results about "Combination drug" patented technology

The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for tumor precise targeted medication based on individual mutation information, which comprises a data processing layer, a variation annotation and function prediction layer, a knowledge base integration layer and a scheme decision-making engine and report visualization module. According to the intelligent decision-making system for tumor precise targeted medication based on individual mutation information, a rule engine and a prediction model are combined, dynamic priority ranking is output, multi-model fusion decision making is achieved, and clinical scene deep adaptation is achieved by predicting primary and secondary drug resistance, calculating liver and kidney function adjusting dosage and generating a combined medication time sequence scheme; through an individualized drug delivery scheme, combination drug use optimization is achieved, a visual clinical report is generated, clinical executable operation is further strengthened, and through algorithm quantification, a dynamic knowledge graph, AI auxiliary decision making and a clinical operation closed loop, the next-generation technical research direction of a tumor precise drug use system can be represented.

The invention provides a combined medicine recommendation method based on multi-modal alignment. A core module of the recommendation method comprises a cloth perception multi-modal medicine alignment module, a time sequence multi-view patient aggregation module and a combined medicine recommendation module. According to the recommendation method, electronic health records EHRs serve as a data source, multi-modal information matched with physical signs of a patient and medicine application characteristics is obtained, effective alignment and fusion are conducted on the multi-modal information through the core module, and suggestion data matched with the multi-modal information and composed of multiple medicines are generated. A DDI loss function and a dynamic weighting strategy are introduced to process conflicts among different drugs in the generated suggestion data so as to output safe suggestion data, and it is avoided that conflicting drugs are recommended in the suggestion data; according to the method, personalized, high-safety, scientific and reasonable drug combination suggestions can be provided.

The application provides a combination drug of a PLA2G7 inhibitor and a chemotherapeutic drug and its use in resisting triple-negative breast cancer, and belongs to the technical field of medicines. The combination drug is a PLA2G7 inhibitor and a chemotherapeutic drug in the same or different specifications of unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. The application first discovers and proves that the PLA2G7 inhibitor Darapladib can significantly enhance the anti-tumor activity of paclitaxel, 5-fluorouracil or cisplatin on triple-negative breast cancer, and meanwhile, the combination of the PLA2G7 inhibitor and paclitaxel has a synergistic effect in down-regulating the phosphorylation level of STAT3 protein in cancer cells and inhibiting the growth and proliferation of cancer cells; the combination of the PLA2G7 inhibitor and 5-fluorouracil also shows a synergistic effect in inhibiting the growth and proliferation of cancer cells. The application provides a new and effective combination drug strategy for improving the treatment effect of the chemotherapeutic drug on triple-negative breast cancer.

The invention discloses a composition, a medicine with the composition and application of the composition. The composition comprises radix aconiti carmichaeli and other qi promoting components, a blood stasis dispersing component; components for warming spleen and stomach, dispelling cold, reviving yang and tonifying spleen Liquorice; a blood generating and activating component; a wind-cold dispersing component; a kidney reinforcing component; the composition disclosed by the invention has a good antiviral effect, and can assist qi and blood generation so as to transform cold-dampness, so that antiviral effect is realized, and meanwhile, the body function is improved.

This invention provides the application of a composition in the preparation of drugs for osteoarthritis, belonging to the field of arthritis technology. The composition comprises tofu glycosides, N-acetylcysteine, seaweed peptides, and PDGF. The combination of these drugs significantly enhances the chondrogenic differentiation and migration capacity of chondrocyte stem cells under inflammatory conditions. Furthermore, in an SD rat knee osteoarthritis model, chondrocyte stem cells treated with the enhanced culture medium reduced the Wakitani histological score from 8.83 to 2.17±0.98, demonstrating a superior repair effect compared to traditional methods. Therefore, this invention provides a foundation for the efficient treatment of osteoarthritis.

This invention discloses a trimethyl chitosan-hyaluronic acid-FMNL2 siRNA nanomedicine and its applications. The siRNA molecule consists of a sense strand and an antisense strand, which are anti-complementary to form a double-stranded RNA structure. Each of the sense and antisense strands independently contains two pendant deoxythymidines at its 3' end. The nanomedicine uses trimethyl chitosan as its core framework, efficiently encapsulating the siRNA molecule through electrostatic interactions, and then modifying hyaluronic acid through electrostatic interactions to form core-shell structured nanoparticles. This invention forms a complete technology chain from target validation, siRNA sequence design, nanodelivery system construction, in vivo and in vitro efficacy verification to the development of combination drug strategies. It also provides quantifiable efficacy evaluation biomarkers, offering a clear basis for clinical patient screening and efficacy monitoring.

The application discloses application of gynostemma pentaphyllum saponin H combined with azole drugs in preparation of antifungal drugs and the antifungal drugs, and relates to the technical field of antifungal drugs. It is found through systematic in-vitro drug sensitivity test that natural product gynostemma pentaphyllum saponin H combined with specific azole antifungal drugs (especially posaconazole POS) can produce significant synergistic antifungal effect, especially for clinical thorny aspergillus, candida, new cryptococcus and dark fungi. The combination strategy can significantly reduce the minimum inhibitory concentration of azole drugs, reverse drug resistance, and is effective for multi-drug resistant strains (such as candida auris). The application provides an efficient and low-toxicity new combination drug scheme for overcoming the increasingly serious fungal drug resistance problem.

The present application relates to the technical field of biological pharmacy, in particular to a combined drug for treating colitis and application thereof, wherein the volume ratio of Coptis exosome and Salmonella outer membrane vesicle in the combined drug is 1-2:1-3; the concentration of the Coptis exosome and the Salmonella outer membrane vesicle is 9-11 mg / mL. The present application overcomes the limitation of single treatment strategy by innovatively combining the Coptis exosome and the Salmonella outer membrane vesicle, significantly improves the treatment effect, and avoids the side effects of existing drugs. The present application has lower treatment cost, is safer and has no drug resistance problem, and can provide a more effective, safe and economical treatment method for inflammatory diseases such as colitis.

Use of a quinazoline compound and a third-generation epidermal growth factor receptor (EGFR) inhibitor in a combined drug for treating non-small cell lung cancer. The quinazoline compound comprises at least one of a quinazoline derivative represented by formula (I), a salt thereof, a solvate thereof, a hydrate thereof, and a polymorph thereof.

The invention discloses an application of a GABAA alpha 6 receptor knockout substance and a combined drug thereof in preparation of a bladder cancer treatment product. The invention provides an application of a substance for knocking out a GABAA alpha 6 receptor gene and a macrophage inhibition drug in preparation of a tumor treatment product. The invention also provides application of a substance for knocking out the GABAA alpha 6 receptor gene and a macrophage inhibition drug in preparation of a product for inhibiting tumor progression. By knocking out the GABAA alpha6 receptor gene, the regulation effect of the GABAA alpha6 receptor gene on CD8 + T cell functions is researched, the application value of the GABAA alpha6 receptor gene in bladder cancer treatment is verified, and a new strategy is provided for clinical treatment.

The invention discloses a composition, a medicine containing the composition, a combined medicine and application. The composition comprises: a first component for promoting the circulation of qi; the second component is used for dispersing blood stasis; the third component is selected from dried ginger, rhizoma kaempferiae, rhizoma galangae or rhizoma curcumae longae; the fourth component is selected from liquorice; the fifth component is selected from angelica sinensis, radix angelicae pubescentis, rhizoma drynariae, cortex acanthopanacis or teasel root The sixth component is used for dispersing wind-cold, and the seventh component is used for reinforcing the kidney; the composition disclosed by the invention has a good antiviral effect, assists qi and blood generation to achieve the effects of transforming cold-dampness and pathogenic qi, retaining healthy qi and assisting blood generation to kill viruses, and meanwhile, regulates qi and blood circulation and strengthens body functions.

The present application belongs to the field of chemical medicine, and particularly relates to a combined drug for preventing and / or treating prostate cancer, use and pharmaceutical composition thereof. The combined drug of the present application is an immune cell with enhanced infiltration degree and a galectin-1 inhibitor; the immune cell with enhanced infiltration degree is a natural killer (NK) cell with TTTY15-USP9Y chimera RNA knocked out, which can increase the infiltration degree and anti-tumor activity of the NK cell in the prostate cancer microenvironment, and the activated NK cell has stronger killing effect on tumor cells in vitro. The present application combines the immune cell with enhanced infiltration degree and the galectin-1 inhibitor, and the combination shows synergistic effect in treating prostate cancer, and has wide application prospect.

The application discloses application of cryptoxanthin in preparation of a combination drug for treating lenalidomide-resistant multiple myeloma, and relates to the technical field of medicines.The application verifies the effect and potential mechanism of betaCRY in treating LEN-resistant MM through in-vivo and in-vitro experiments, specifically, betaCRY can inhibit the expression level of FSP1 protein in LEN-resistant tumors, thereby inducing the occurrence of ferroptosis, and then significantly reducing the activity of LEN-resistant tumor cells, and finally achieving the purpose of overcoming LEN tumor drug resistance.The discovery in the application proves that a plant extract serves as a new FSP1 inhibitor in the treatment of LEN-resistant MM cells, and provides a theoretical basis for further using betaCRY to treat LEN-resistant MM in clinic.Therefore, the application has a good application prospect in the field of treating drug-resistant MM.

The invention discloses a mesenchymal stem cell preparation and application thereof, and belongs to the technical field of cell biology. The mesenchymal stem cell preparation is a mesenchymal stem cell pretreated by a combined drug of ziyuglycoside II and shikonin. Through drug pretreatment, the antioxidant capacity of the mesenchymal stem cells is synergistically enhanced, the survival rate of the cells after transplantation is enhanced, the treatment effect of the cells on the NAFLD hepatocytes is remarkably enhanced, and lipid accumulation in the hepatocytes is effectively reduced. Therefore, the invention provides a novel method for enhancing the treatment capacity of the mesenchymal stem cells NAFLD, the method is suitable for bone marrow and umbilical cord mesenchymal stem cells, and an efficient and reliable preparation and an optimization scheme are provided for clinical stem cell treatment of the NAFLD.

The present application relates to the technical field of biological medicine, and in particular to a pharmaceutical composition for treating hepatocellular carcinoma and application thereof, wherein the pharmaceutical composition comprises metformin or a pharmaceutically acceptable salt thereof and obeticholic acid or a pharmaceutically acceptable salt thereof, and the weight ratio of the metformin to the obeticholic acid is 1:0.05-0.2. It is found for the first time that the combination of metformin and farnesol X receptor agonist can regulate the AMPK / mTOR pathway and the immune recruitment mediated by CXCL16 in a synergistic manner, inhibit the proliferation of tumor cells, repair the recruitment function of NKT cells in the microenvironment of hepatocellular carcinoma, and realize the dual anti-tumor effect of metabolic inhibition and immune enhancement. Animal experiments show that the tumor inhibition rate of the combination drug group is significantly better than that of the single drug group, and the safety is good.

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.

The present invention relates to the field of biomedicine and relates to a combined pharmaceutical composition used for treating small cell lung cancer, the composition comprising an anti-PD-L1 antibody and anlotinib, and having good anti-small cell lung cancer activity.

The application discloses a kind of attenuated salmonella load adjuvant nano combination medicine, the combination medicine is modified to bacterial surface by means of amino and carboxyl condensation reaction, adamantane is simultaneously modified to adjuvant nano medicine surface using diselenium dynamic bond, then the host-guest interaction of adamantane and cyclodextrin is used to assemble two, and then nano medicine is stably combined on the surface of attenuated salmonella.Diselenium dynamic bond can be broken by ultrasound response, so as to realize the effect of drug release.This combination medicine has the tumor targeting enrichment ability of bacteria and the release characteristics of adjuvant nanoparticles under the action of ultrasonic wave, can realize targeted delivery and deep penetration in tumor tissue, and obtain significant tumor inhibition effect under ultrasonic stimulation.The experimental results show that the combination medicine exhibits good therapeutic effect in inhibiting tumor growth, and has excellent biological safety.

The application provides a combined medicine containing a nitrothiazolyl acid amide derivative and application thereof, and belongs to the field of chemical medicines. The combined medicine contains component A and component B which are administered simultaneously or separately and have the same or different specifications, and a pharmaceutically acceptable carrier. The component A is a nitrothiazolyl acid amide derivative shown in formula I, or a pharmaceutically acceptable salt thereof, or a crystal form thereof. The component B is a fatty acid, or a pharmaceutically acceptable salt thereof, or a crystal form thereof. The combined medicine is used for preventing and / or treating infections and related diseases. The combined medicine can produce a synergistic effect, is used for treating viral, bacterial and parasitic infections and related diseases, and has a good treatment effect. Meanwhile, the combined medicine has good safety in use, provides a new choice for clinically treating infections and related diseases caused by infections, and has a good application prospect.

The present invention relates to combinations comprising a checkpoint inhibitor and a c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of the free base of Compound 1, as well as crystalline forms of salts of Compound 1, in combination with a checkpoint inhibitor. The invention further relates to methods of treating cancer by administering Compound 1 as a single agent or a combination described herein.

This invention belongs to the field of biomedical technology, specifically relating to triptolide liposomes (TP-lipo), their combined use, and their application in the prevention and treatment of tumors. To enhance the efficacy of triptolide in the treatment and prevention of tumors such as pancreatic cancer, cervical cancer, ovarian cancer, and colorectal cancer, and to improve its bioavailability and clinical application while reducing toxicity, this invention uses HSPC, DOPS, and cholesterol as liposome components to encapsulate triptolide monomers, thus preparing TP-lipo. Experiments have shown that TP-lipo exhibits anti-tumor activity: it directly kills tumor cells and reverses the immunosuppressive microenvironment, making it a potential drug for tumor treatment. TP-lipo, when used in combination with PD-1 antibodies, or in combination with radiotherapy, chemotherapy, or surgery, demonstrates a potent and synergistic anti-tumor effect with low toxicity. Therefore, the TP-lipo of this invention provides more clinical strategies for tumor treatment.

The present invention relates to novel compounds of general Formula I with multifaceted pharmacological activities. The compounds of the invention exhibit SGLT1, SGLT2, and DPP4 inhibition. The present invention also provides processes and intermediates to obtain the compounds of the invention, pharmaceutical compositions comprising encompasses the compounds, processes and intermediates for the synthesis of the compounds, pharmaceutical compositions, combinations, medicaments, therapeutical uses and methods for the treatment of diseases, for instance, cardiovascular and renal diseases, including heart failure, chronic kidney disease, diabetes mellitus, diabetic nephropathy and myocardial infarction. [Chem. 1] Compound of Formula I (I)

To provide a new antitumor agent.SOLUTION: The present invention provides an antitumor agent containing a glutathione concentration lowering agent or a glutathione S-transferase inhibitor as an active ingredient to be administered simultaneously with an aldehyde dehydrogenase inhibitor, or an antitumor agent containing an aldehyde dehydrogenase inhibitor as an active ingredient to be administered simultaneously with an effective amount of a glutathione concentration lowering agent or a glutathione S-transferase inhibitor, or a combination drug containing an aldehyde dehydrogenase inhibitor and a glutathione concentration lowering agent or a glutathione S-transferase inhibitor as active ingredients. The aldehyde dehydrogenase inhibitor is a compound represented by the following formula (I) or a pharmacologically acceptable salt thereof.SELECTED DRAWING: None

The present disclosure provides: modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I); pharmaceutical compositions containing at least one such modulator; methods of using such modulators and pharmaceutical compositions to treat CFTR-mediated diseases, including cystic fibrosis; combination pharmaceutical compositions and combination therapies employing these modulators; and processes and intermediates for making such modulators.

This disclosure relates to a combination drug regimen comprising an anti-KMA antibody, IMiD / CELMoD, and a steroid. Such a combination may be used for the treatment of multiple myeloma.

The application discloses a traditional Chinese medicine combined medicament for treating 2,4-dichlorophenoxyacetic acid-induced liver injury of livestock and poultry, which is prepared by compounding procyanidin B3, cryptotanshinone and resveratrol, and the three components have synergies and can effectively improve the 2,4-dichlorophenoxyacetic acid-induced liver injury problem of livestock and poultry. The application has simple formula and simple preparation process, can be developed into green and safe liver-protecting veterinary drugs and functional feed, and has good application and popularization value in the field of livestock and poultry breeding.

This invention relates to the field of biomedical technology, specifically to an antifungal nanoparticle, a combination drug, and its application. The antifungal nanoparticle is prepared by covalently linking the aptamer AU1 to drug-loaded silk fibroin nanoparticles via amide bonds. The mass ratio of the drug-loaded silk fibroin nanoparticles to the aptamer AU1 is 20:0.5~2.0. The antifungal nanoparticles of this invention are prepared by a desolvation method using voriconazole-loaded silk fibroin nanoparticles, and the targeting aptamer AU1 is attached to their surface using a carbodiimide chemical cross-linking method. This allows for specific recognition of Candida albicans, increasing drug accumulation at the infection site. Further combination with methylene blue-mediated photodynamic therapy can disrupt biofilm structures, enhance nanoparticle penetration, achieve synergistic bactericidal activity, and reduce systemic toxicity, providing a novel, highly effective, and low-toxicity treatment strategy for fungal biofilm infections.

The application provides a method for synchronously detecting multiple cell death modes in a tissue slice based on multiplex immunofluorescence, and belongs to the technical field of biological detection. The application realizes the synchronous labeling and visualization of multiple cell death modes in a single tissue slice, significantly improves the detection efficiency and saves precious samples; by integrating key biomarkers covering main cell death modes in the same detection system, a self-defined interpretation scheme based on multi-marker expression combination is constructed, effectively reducing the error caused by non-specific expression of a single marker, improving the reliability and rationality of the death mode classification, and providing a general solution for rapid screening of complex cell death networks. The application is suitable for anticancer drug efficacy evaluation, combination drug regimen screening and disease mechanism research, and has important scientific research value and clinical conversion prospect.